Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments.
CDI's at-home breath test kits for SIBO, IMO, and carbohydrate malabsorption help providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments.
CDI’s cost-effective portfolio of diagnostic solutions results in expedited treatment plans focused on patient-centric principles. It supports meaningful GI health outcomes with more precise and timely results from its experienced lab staff.
Its expansive portfolio includes non-invasive at-home hydrogen and methane breath tests for Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), as well as fructose, lactose, and sucrose malabsorption.
CDI tests are easy-to-use, quick, and safe for patients and support meaningful GI health outcomes by helping steer each practitioner’s approach to dietary modification, homeopathic remedies, nutritional supplementation, immune support, high-quality probiotics, and additional testing.
Founded in 2015 in Salem, Massachusetts, and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, CDI has partnerships with leading health systems, hospitals, and private practices worldwide.
CDI's at-home breath test kits for SIBO, IMO, and carbohydrate malabsorption help providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments.
Description of quality control process.